OncoDiscover® is a patented, DCGI-approved blood test designed to detect and monitor circulating tumor cells (CTCs) in real time. Built on advanced nanoparticle and fluorescence technology, this minimally invasive diagnostic tool offers a powerful alternative to traditional imaging methods—capable of predicting metastatic relapse, monitoring treatment response, and detecting minimal residual disease (MRD) early in the patient journey.
Unlike static imaging, OncoDiscover allows clinicians to track the dynamic progression of cancer at the cellular level, helping inform better treatment decisions. By capturing the heterogeneity of tumors and detecting CTC clusters, it provides insights that imaging or tissue biopsies often miss. This technology also enables detection of actionable targets like PD-L1, EGFR, and HER2 on tumor cells—empowering more personalized therapy strategies.
Validated across multiple cancer types including breast, lung, colorectal, ovarian, and head and neck, OncoDiscover supports improved outcomes through proactive monitoring. With high sensitivity and a cost-effective design, it brings leading-edge cancer surveillance within reach for more patients around the world.